Centogene launches whole genome sequencing test CentoGenome for rare disorders
Peshkova/iStock via Getty Images
- Centogene (NASDAQ:CNTG) said it launched a next generation sequencing (NGS)-based assay called NEW CentoGenome.
- NEW CentoGenome is a commercially available Whole Genome Sequencing (WGS) test on the market for rare and neurodegenerative disorders – covering almost all disease-causing variants, in a single assay, the company added.
- The company said it combines technology and streamlined CE-IVD bioinformatics pipeline with the CENTOGENE Biodatabank, consisting of ~700K patients representing over 120 countries.
- The test reduces time and resources by avoiding stepwise testing and helps deliver rapid and reliable diagnosis.